Industry

Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors

– AB-201 is a novel and highly specific HER2-directed cell therapy candidate developed using Artiva’s proprietary CAR technology and scaled AlloNK™ manufacturing platform – Clinical evaluation of AB-201 in HER2-positive cancers is planned to initiate in 1H2023 SAN DIEGO–(BUSINESS WIRE)–#CARNK—Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic … [Read more…]

Vatica Health Recognized in KLAS 2022 Emerging Solutions Top 20 Report

ATLANTA–(BUSINESS WIRE)–The healthcare research firm KLAS has named Vatica Health to its 2022 Emerging Solutions Top 20 list, which recognizes innovative companies that have the greatest potential to impact and disrupt the healthcare market. Vatica, the leader in prospective, PCP-centric risk adjustment and clinical quality solutions, is the only risk adjustment solution to earn a … [Read more…]

Atrium Health CISO Todd Greene Joins Semperis as Strategic Advisor

Atrium Health Recently Participated in Semperis’ $200M+ Funding Round, Led by KKR HOBOKEN, N.J.–(BUSINESS WIRE)–Semperis, a pioneer of identity-driven cyber resilience for enterprises, today announced the addition of Todd Greene, Vice President & Enterprise CISO at Charlotte, North Carolina-based Atrium Health, to its Strategic Advisory Board. Atrium Health participated in Semperis’ recent Series C funding … [Read more…]

ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors

Anzu Partners led the $14M financing round with participation from Amgen Ventures and EDBI ImmunoScape’s Deep Immunomics and machine learning platforms comprise a highly effective method for the discovery of T-cell receptor (TCR) candidates, targeting novel antigens such as cancer-specific shared splice variants and human endogenous retroviral elements The company is poised to take a … [Read more…]

Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment

GLY-200 is a First-in-Class, Oral, Gut-Targeted Approach for Treatment of Type 2 Diabetes and Related Metabolic Conditions Newly Released Phase 1 Biomarker Data is Consistent with Effects of Roux-en-Y Gastric Bypass Surgery and Duodenal Exclusion Devices Initial Data from Phase 2 Trial Evaluating GLY-200 in Patients with Type 2 Diabetes Anticipated in Early 2023 BOSTON–(BUSINESS … [Read more…]

Trio Health and Allergy Partners to Form National Allergy and Asthma Patient Registry

LOUISVILLE, Colo. & ASHEVILLE, N.C.–(BUSINESS WIRE)–Trio Health (Trio), a leading provider of real-time data on real-world patients, and Allergy Partners, the nation’s largest single speciality practice, today announced a strategic partnership in which Allergy Partners will anchor the formation of a national allergy and asthma patient registry, leading the path forward in real world evidence … [Read more…]

Atavistik Bio Announces Formation of Scientific Advisory Board

Scientific Advisory Board Strengthens Atavistik Bio’s Mission of Harnessing the Power of Protein-Metabolite Interactions to add a New Lens to Drug Discovery CAMBRIDGE, Mass.–(BUSINESS WIRE)–Atavistik Bio, a pre-clinical biotechnology company that is leveraging their scalable and systematic platform to identify novel regulatory sites on proteins to restore function in disease, announced the formation of its … [Read more…]

Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives

Industry-leading talent joins leadership team as company accelerates its CLAROMER™ drug platform Tony Verco, MD, MBA, appointed Chief Medical Officer Beth Burnside, PhD, appointed Senior Vice President of Research and Development Strategy Donald Treacy, Jr., PhD, appointed Senior Vice President, Development Operations AUSTIN, Texas–(BUSINESS WIRE)–Maxwell Biosciences (“Maxwell”), a preclinical drug platform company focused on the … [Read more…]

The Australian Research Council Centre of Excellence in Synthetic Biology and Twist Bioscience Partner to Foster and Accelerate Synthetic Biology Research in Australia

SOUTH SAN FRANCISCO, Calif. & SYDNEY–(BUSINESS WIRE)–Twist Bioscience (Nasdaq: TWST) and the Australian Research Council (ARC) Centre of Excellence in Synthetic Biology (CoESB) today announced a partnership that will enable CoESB members and partners to order a wide range of Twist products that facilitate research and development. Australia’s commitment to the growing market of synthetic … [Read more…]

National Hemophilia Foundation Launches “Pathway to Cures,” a Venture Philanthropy Fund to Accelerate the Development of Transformational Therapies and Technologies for Inheritable Blood Disorders

Fund starting with $3.5 million of commitments; targeting $20 million Venture Philanthropy model to transform the therapeutic development landscape for disease category impacting more than 20 million people NEW YORK–(BUSINESS WIRE)–National Hemophilia Foundation (NHF), the leading global organization funding inheritable blood disorders research, education, and community advocacy, today announced the launch of Pathway to Cures … [Read more…]